Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CART22
i
Other names:
CART22, CART22-65s
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
University of Pennsylvania
Drug class:
CD22-targeted CAR-T immunotherapy
Related drugs:
‹
CAR-T19/CAR-T22 immunotherapy (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
AUTO1/22 (0)
AUTO3 (0)
Anti-CD19/CD20/CD22 CAR T-Cells (0)
Anti-CD22 CAR-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART-19/22 (0)
CD19 and CD22 targeted prime CAR-T (0)
CD19-CD22 CAR-T (0)
CD19/CD22 CAR T-cells (0)
CD19/CD22 CAR-T cell therapy (0)
CD19/CD22 chimeric antigen receptor T cell (0)
CD19/CD22 dual-target CAR-T (0)
CD19x22 CAR T (0)
CD22-CART (0)
CD22-targeted CAR-T cell therapy (0)
CD22/CD19 CAR T (0)
CT120 (0)
CTA101 (0)
GC022F (0)
HY004 (0)
IMJ995 (0)
JCAR018 (0)
LB1909 (0)
LCAR-AIO (0)
MB-CAR-T19-22 (0)
SCRI-CAR19x22v2 (0)
SCRI-CAR22v2 (0)
Senl_22 (0)
Senl_H19x22P (0)
ThisCART22 (0)
UCART20x22 (0)
UCART22 (0)
anti-CD19/CD22 CAR-T cells (0)
anti-CD22 CAR T (0)
anti-CD22 CAR-T cell therapy (0)
anti-CD22 CAR-T therapy (0)
anti-CD22-CAR (0)
autologous TriCAR T (0)
CRG-022 (0)
multi-CAR-T cell therapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
CAR-T19/CAR-T22 immunotherapy (1)
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR (0)
4SCAR-T (0)
AUTO1/22 (0)
AUTO3 (0)
Anti-CD19/CD20/CD22 CAR T-Cells (0)
Anti-CD22 CAR-T Cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
CAR20.19.22 T (0)
CART-19/22 (0)
CD19 and CD22 targeted prime CAR-T (0)
CD19-CD22 CAR-T (0)
CD19/CD22 CAR T-cells (0)
CD19/CD22 CAR-T cell therapy (0)
CD19/CD22 chimeric antigen receptor T cell (0)
CD19/CD22 dual-target CAR-T (0)
CD19x22 CAR T (0)
CD22-CART (0)
CD22-targeted CAR-T cell therapy (0)
CD22/CD19 CAR T (0)
CT120 (0)
CTA101 (0)
GC022F (0)
HY004 (0)
IMJ995 (0)
JCAR018 (0)
LB1909 (0)
LCAR-AIO (0)
MB-CAR-T19-22 (0)
SCRI-CAR19x22v2 (0)
SCRI-CAR22v2 (0)
Senl_22 (0)
Senl_H19x22P (0)
ThisCART22 (0)
UCART20x22 (0)
UCART22 (0)
anti-CD19/CD22 CAR-T cells (0)
anti-CD22 CAR T (0)
anti-CD22 CAR-T cell therapy (0)
anti-CD22 CAR-T therapy (0)
anti-CD22-CAR (0)
autologous TriCAR T (0)
CRG-022 (0)
multi-CAR-T cell therapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
sequential different B cell antigen-targeted CAR T-cell therapy (0)
›
Associations
News
Trials
Phase
Status
Apply
Phase
Status
Apply
CART22 Alone or in Combination With huCART19 for ALL (NCT03620058)
Phase 1
University of Pennsylvania
University of Pennsylvania
Active, not recruiting
Phase 1
University of Pennsylvania
Active, not recruiting
Last update posted :
05/24/2024
Initiation :
09/27/2018
Primary completion :
01/01/2036
Completion :
01/01/2036
CD22
|
CD22 expression
|
CART22 • huCART19
CD22 Redirected Autologous T Cells for ALL (NCT02650414)
Phase 1
University of Pennsylvania
University of Pennsylvania
Recruiting
Phase 1
University of Pennsylvania
Recruiting
Last update posted :
02/05/2024
Initiation :
01/13/2016
Primary completion :
12/01/2037
Completion :
12/01/2037
CD22
|
CD22 expression
|
CART22
Co-administration of CART22-65s and huCART19 for B-ALL (NCT05674175)
Phase 1/2
Stephan Grupp MD PhD
Stephan Grupp MD PhD
Recruiting
Phase 1/2
Stephan Grupp MD PhD
Recruiting
Last update posted :
12/19/2023
Initiation :
01/25/2023
Primary completion :
01/15/2027
Completion :
01/15/2029
CD22
|
CD19 expression • CD22 expression
|
Kymriah (tisagenlecleucel-T) • CART22 • huCART19
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login